Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 12/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17882287 | 0.77 | RIPK1 (1.00) | RIPK1DPP4DPP8DPP9DPP7 | |
| SCHEMBL17882289 | 0.77 | RIPK1 (0.65) | RIPK1MEN1KMT2A | |
| SCHEMBL29046387 | 0.72 | RIPK1 (0.66) | RIPK1MEN1KMT2ADPP4DPP9 | |
| SCHEMBL29912817 | 0.71 | RIPK1 (0.61) | RIPK1DPP4FAPDPP8DPP9 | |
| SCHEMBL17882376 | 0.71 | RIPK1 (0.61) | RIPK1DPP4FAPDPP8DPP9 | |
| SCHEMBL29912938 | 0.71 | RIPK1 (1.00) | RIPK1DPP4DPP8DPP9DPP7 | |
| SCHEMBL17882413 | 0.71 | RIPK1 (1.00) | RIPK1DPP4DPP8DPP9DPP7 | |
| SCHEMBL17882182 | 0.70 | RIPK1 (0.87) | RIPK1MEN1KMT2A | |
| SCHEMBL29912757 | 0.69 | RIPK1 (0.61) | RIPK1 | |
| SCHEMBL17874116 | 0.69 | RIPK1 (0.61) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682319-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682319-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885EPHX2 3742/4885MEN1 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.